Home » Business, Health & Medicine, Hospitality » Emixustat (Macular Edema and Macular Degeneration) Market 2023 – New Research Report Published By Radiant Insights
Radiant Insights, Inc. adds a report titled “Emixustat (Macular Edema and Macular Degeneration) Industry 2023 Market Research Report” providing detailed information about the global market. The report is an excellent piece of study for investors who are looking towards the market.

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector.

The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Read Complete Report with TOC:

Emixustat hydrochloride (formerly known as ACU-4429) is an orally-dosed VCM that is designed to be selective for rod photoreceptors and is being developed for the treatment of GA associated with dAMD. This was the first internally-developed compound by Acucela, a Seattle-based biotechnology company. Acucela has one issued US patent (No. 7,982,071) and seven pending US patents for emixustat, all of which will expire in or around 2029.

You Can Get This Report On Linkedin: 


• Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

• Detailed information on Emixustat including product description, safety and efficacy profiles as well as a SWOT analysis. 

• Sales forecast for Emixustat for the top country from 2013 to 2023.

• Sales information covered for the US, France, Germany, Italy, Spain, UK and Japan

About Us

Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. We assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, our experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.

For More Information, Visit: Radiant Insights

Click Here For Other Reports: 

Phone Case Market:

Modified Bitumen Membrane Market:

Media Contact
Company Name: Radiant Insights, Inc.
Contact Person: Michelle Thoras, Corporate Sales Specialist – USA
Email: sales@radiantinsights.com
Phone: (415) 349-0054, Toll Free: 1-888-202-9519
Address:28 2nd Street, Suite 3036
City: San Francisco
State: Califonia
Country: United States
Website: http://www.radiantinsights.com/research/emixustat-macular-edema-and-macular-degeneration-forecast-and-market-analysis-to-2023

Comments are closed.